Lantus Loss Drags Down Sanofi's Diabetes Franchise

A nearly 20% drop in US sales of Sanofi's top-seller Lantus was largely to blame for a 6.6% fall in its diabetes franchise sales in the third quarter, leading the French pharma to lower its forecasts for its leading therapy segment.

A nearly 20% drop in US sales of Sanofi's top-seller Lantus was largely to blame for a 6.6% fall in its diabetes franchise sales in the third quarter, leading the French pharma to lower its forecasts for its leading therapy segment.

The announcement during its third quarter results presentation wiped nearly 5% off Sanofi's share price, which was down to around...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category